Sorrento Therapeutics (NASDAQ:SRNE) is a clinical-stage biopharmaceutical company focused on the development of therapies in immuno-oncology, inflammatory diseases and pain management. Leveraging proprietary antibody, small molecule and cell therapy platforms, Sorrento aims to advance next-generation treatment candidates that address unmet medical needs in oncology and chronic pain without reliance on traditional opioids.
The company’s immuno-oncology pipeline encompasses monoclonal antibodies, antibody-drug conjugates and engineered cell therapies designed to target solid tumors and hematologic malignancies. In pain management, Sorrento originally incubated a portfolio of non-opioid analgesics—such as resiniferatoxin—for chronic pain conditions, later spinning out this business into a dedicated entity. Sorrento has also applied its antibody discovery engine to develop COVID-19 neutralizing antibodies and related diagnostic assets.
Founded in 2009 and headquartered in San Diego, California, Sorrento operates research and development facilities in the United States, with strategic collaborations extending to Asia and Europe. Through partnerships with academic institutions and industry collaborators, the company seeks to accelerate preclinical studies and clinical trials across multiple therapeutic areas.
Under the leadership of founder, chairman and CEO Dr. Henry Ji, M.D., Ph.D., Sorrento continues to build its pipeline and expand its technology platforms. As a clinical-stage organization, the company’s objective is to translate its research innovations into approved therapies that deliver meaningful benefits to patients and long-term value to stakeholders.
